


RealRate

### PHARMACEUTICAL 2020

**EMERGENT** 

# Emergent BioSolutions Inc. Rank 56 of 362





### PHARMACEUTICAL 2020

#### **EMERGENT**



## Emergent BioSolutions Inc. Rank 56 of 362

The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 303% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 389% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	686,200
Cost of Goods Sold	433,500
Intangible Assets	979,500
Liabilities, Current	216,300
Liabilities, Non-Current	932,600
Other Assets	119,300
Other Compr. Net Income	-64,000
Other Expenses	58,700
Other Liabilities	89,900
Other Net Income	0
Property and Equipment	542,300
Research and Development	226,200
Revenues	1,106,000
Selling, General and Administrative Expense	273,500

Output Variable	Value in 1000 USD
Assets	2,327,300
Liabilities	1,238,800
Expenses	991,900
Stockholders Equity	1,088,500
Net Income	114,100
Comprehensive Net Income	82,100
Economic Capital Ratio	86%